# Serum biomarker trajectory clusters predict functional outcome and quality of life for traumatic brain injury

**Authors:** Thanh Son Do, Chantal Carnes, Zhihui Yang, Firas Kobeissy, Hamad Yadikar, Gayla Olbricht, Olli Tenovuo, Jussi P Posti, Ewout W Steyerberg, Lindsay Wilson, Nicole von Steinbüchel, Endre Czeiter, Andras Buki, David K Menon, Andrew I R Maas, Kevin K Wang, Tayo Obafemi-Ajayi

PMC · DOI: 10.1093/braincomms/fcag055 · Brain Communications · 2026-02-23

## TL;DR

Tracking changes in blood biomarkers over time in TBI patients can predict long-term recovery and quality of life better than single measurements.

## Contribution

The study introduces biomarker trajectory profiling as a novel method for predicting outcomes in TBI patients using longitudinal serum data.

## Key findings

- High biomarker trajectory profiles are strongly linked to poor functional recovery and higher mortality in TBI patients.
- Low trajectory profiles correlate with better recovery and quality of life outcomes.
- Longitudinal biomarker monitoring provides more accurate prognostic information than single-timepoint measurements.

## Abstract

Serum brain-enriched biomarkers are increasingly employed in the clinical evaluation of traumatic brain injury (TBI) to assist with triage, neuroimaging decisions, and prognostication. However, the potential of temporal biomarker trajectories to inform disease monitoring and long-term outcomes remains underexplored. We aim to identify distinct biomarker trajectory (TRAJ) profiles in traumatic brain injury patients and to examine their associations with long-term clinical outcomes. The study included 373, CT-positive Intensive Care Unit (ICU) traumatic brain injury patients (256 with initial Glasgow Coma Scale 3–12) from the Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI) core study who had at least two serum samples collected between days 1 and 5 post-injury. Six biomarkers -glial fibrillary acidic protein, ubiquitin C-terminal hydrolase-L1, neurofilament light chain, Tau, S100B, and neuron-specific enolase- were analysed. Optimal cluster solutions were determined using a composite validation index derived from seven internal clustering metrics. Distinct high and low trajectory classes emerged for all biomarkers; each comprising at least 40% of the cohort for five of the biomarkers. Cross-biomarker concordance analysis identified composite high (n = 104) and low (n = 110) TRAJ profiles. Key metrics for evaluating patient outcomes include Glasgow Outcome Scale Extended (GOSE), mortality, and Quality of Life after Brain Injury Overall Scale (QoLIBRI-OS) at 3, 6, and 12 months as well as a prognostic incremental value analysis using a conventional prediction model: International Mission for Prognosis and Analysis of Clinical Trials in TBI (IMPACT). High TRAJ membership is strongly associated with poor functional recovery (GOSE 1–4 at 3–12 months; odds ratio (OR) 8.79 [95% confidence interval (CI): 4.56-16.97]—12.29 [95%CI: 6.19–24.40], P < 0.001) and increased 180-day mortality (OR (14.84 [95%CI: 5.56–39.64], P < 0.001). Conversely, low TRAJ membership predicted favourable recovery (GOSE 6–8 at 3–12 months; OR 7.42 [95%CI: 3.10–17.76]—10.83 [95%CI: 3.65–32.14], P < 0.001) and better quality of life (QoLIBRI-OS ≥52; OR 4.98 [95%CI: 1.92–12.89], P < 0.01). Compared to single day-1 biomarker measurements, trajectory-based profiles yielded larger effect sizes and provided incremental prognostic value when added to the IMPACT prediction model (ΔR² 9–17%, P < 0.05). Overall, repeated biomarker measurements across the acute phase yield superior prognostic accuracy relative to single timepoint assessments. These findings underscore the importance of integrating longitudinal biomarker monitoring into ICU-based traumatic brain injury care and suggest that temporal trajectory profiling may improve prognostic modelling and facilitate more precise patient stratification for both clinical management and interventional studies.

Do et al. report that serum biomarker trajectory profiling on intensive care unit-admitted traumatic brain injury patients reveals distinct high and low temporal patterns associated with functional outcome and mortality. Longitudinal trajectories outperform single measurements, offering significant incremental prognostic value, supporting integration into precision traumatic brain injury care and outcome modelling.

Graphical AbstractFor image description, please refer to the figure legend and surrounding text.

## Linked entities

- **Proteins:** MAPT (microtubule associated protein tau), S100B (S100 calcium binding protein B)
- **Diseases:** traumatic brain injury (MONDO:0858950)

## Full-text entities

- **Genes:** ENO2 (enolase 2) [NCBI Gene 2026] {aka HEL-S-279, NSE}, NEFL (neurofilament light chain) [NCBI Gene 4747] {aka CMT1F, CMT2E, CMTDIG, NF-L, NF68, NFL}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, S100B (S100 calcium binding protein B) [NCBI Gene 6285] {aka NEF, S100, S100-B, S100beta}, UCHL1 (ubiquitin C-terminal hydrolase L1) [NCBI Gene 7345] {aka HEL-117, HEL-S-53, NDGOA, PARK5, PGP 9.5, PGP9.5}, RMDN1 (regulator of microtubule dynamics 1) [NCBI Gene 51115] {aka CGI-90, FAM82B, RMD-1, RMD1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}
- **Diseases:** structural injury (MESH:D020914), lesion (MESH:D009059), Stroke (MESH:D020521), Neurological Disorders (MESH:D009461), CB (MESH:D058617), neurofibrillary tangles (MESH:D055956), inflammatory (MESH:D007249), neurodegenerative diseases (MESH:D019636), injury (MESH:D014947), GOSE (MESH:C538175), head injuries (MESH:D006259), polytrauma (MESH:D009104), intracranial lesions (MESH:D020765), TBI (MESH:D000070642), TRAJ (MESH:D000077962), , neuronal, and axonal injury (MESH:D001480), disability (MESH:D009069), Coma (MESH:D003128), CT abnormalities (MESH:D000014), subarachnoid haemorrhage (MESH:D013345), death (MESH:D003643), brain lesions (MESH:D001927), Brain Injury (MESH:D001930), fatalities (MESH:C565541)
- **Chemicals:** lactate (MESH:D019344), glucose (MESH:D005947)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12970999/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12970999/full.md

## References

67 references — full list in the complete paper: https://tomesphere.com/paper/PMC12970999/full.md

---
Source: https://tomesphere.com/paper/PMC12970999